Enanta Pharmaceuticals | ENTA - Net Income


Enanta Pharmaceuticals reported $-22.29M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Immunic USD -24.37M 2.99M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025